Article Information
History
- July 7, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Olav Engebraaten1,2,
- Christina Yau3,
- Kristian Berg2,4,
- Elin Borgen5,
- Øystein Garred5,
- Maria E.B. Berstad2,
- Ane S.V. Fremstedal2,
- Angela De Michele6,
- Laura van’t Veer3,
- Laura Esserman3 and
- Anette Weyergang2,*
- 1Department of Oncology, Oslo University Hospital, Oslo, Norway and Institute of Clinical Medicine, University of Oslo, Norway
- 2Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Norway
- 3Department of Surgery, University of California San Francisco, California, United States
- 4Department of Pharmacy, University of Oslo, Norway
- 5Department of Pathology, Oslo University Hospital, Oslo Norway
- 6Department of Medicine, Perelman school of Medicine, University of Pennsylvania, United States
- ↵*Correspondent author Address: Oslo University Hospital, Norwegian Radium Hospital, Ullernchausseen 70, 0379 Oslo, Norway, E-mail: anette.weyergang{at}rr-research.no, Phone: (+47) 22 78 14 81, Mobile: (+47) 40 20 45 57, Fax: (+47) 22 78 14 95
Posted July 07, 2021.
RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
